



**FOR IMMEDIATE RELEASE**

*June 2009*

## **High Praise from Collaborators for Ichor Medical Systems' TriGrid Delivery System**

### ***Testimonials Cite Efficiency, Potential, Technological Advantage***

Ichor Medical Systems, a privately-held biotech company founded in San Diego in 1994, is developing products based on the in vivo application of electroporation to enhance intracellular delivery of DNA drugs encoding therapeutic proteins or antigens for vaccines. Ichor's proprietary TriGrid™ Delivery System (TriGrid) is the first and only integrated and fully automated system for electroporation-mediated DNA administration.

Ichor's TriGrid enables safe, effective and reproducible clinical application of electroporation in a manner capable of supporting development and commercialization of DNA-based products. TriGrid is currently being used on three continents in collaborations with some of the world's leading research organizations and medical centers for a wide range of pre-clinical and clinical studies for potential treatments of melanoma, HIV, Hepatitis B, and Avian Flu.

Those who have worked with Ichor and the TriGrid can tell its story better than anyone:

#### ***...about the efficiency:***

"We had been looking into the use of electroporation (EP) to enhance our DNA vaccines in vivo because it has the potential to increase immunogenicity a hundred fold. Working with Ichor, we can significantly improve the efficiency of our DNA vaccines for HIV and flu while potentially lowering costs and decreasing manufacturing, dosage and distribution demands. There's always the possibility that a pandemic flu will come along and the nation only has capacity to make so much vaccine for a small segment of the population. EP through Ichor's TriGrid can significantly increase the efficiency of the vaccine so the same amount can be used to treat more people."

*David Ho, M.D., CEO, Aaron Diamond AIDS Research Center*



***...about the technological superiority:***

“Ichor is significantly ahead of other electroporation technologies on the scientific front. With their TriGrid Delivery System, you don’t have to use complicated positioning when you inject the DNA and then administer the pulse. The TriGrid removes the guesswork. One stick and it’s over, versus two sticks with the lesser technologies. If the patient doesn’t get the desired response [with the TriGrid], it’s not because the electrodes were mispositioned. Other methods can easily produce false negatives. With the TriGrid, anyone can do it. Someone can use the TriGrid in the jungle with a malaria vaccine just as easily as a physician in the comfort of his or her office.”

*John Laszlo, M.D., Ichor Scientific Advisory Board Chairman*

“I think Ichor has a terrific opportunity with their TriGrid to advance cancer therapy, just as one example. Their technology is more promising than other electroporation methods because their delivery system is much more benign and easier for the patient. The needles are very thin, hidden within the TriGrid and, most importantly, are applied in one quick motion. The more efficient the delivery, the better the chance that it will be effective and produce results.”

*Jeffrey Weber, M.D., Ph.D., Director, Donald A. Adam Comprehensive Melanoma Research Center, H. Lee Moffitt Cancer Center, Tampa*

For additional inquiries, please contact:

***Ichor Medical Systems – 858-550-2022***

Dr. May de las Alas  
mdelasalas@ichorms.com  
Direct: 858-550-2022 x108